Treatment Patterns in Metastatic Prostate Cancer

Bayer565 enrolled

Overview

This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives). Additionally, this study will evaluate opioid/analgesic use among lines of therapy in this patient population (secondary objective). The study is descriptive in nature and is meant to provide a greater understanding of the patterns of therapy observed in real-world clinical practice (in the absence of clear guideline recommendations with regards to treatment sequencing), to contribute to a greater understanding of the major cost drivers (thus better-informing payers), and to examine real-world mortality in such patients.

Study Type

OBSERVATIONAL

Enrollment

565

Conditions

Prostatic Neoplasm

Interventions

Xofigo (Radium 223 dichloride,BAY88-8223)DRUG

Retrospective claims analysis. Descriptive analyses of treatment patterns.

Eligibility

Sex: MALEMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Subjects with at least one claim with a primary diagnosis of prostate cancer (International Classification of Diseases(ICD) Clinical Modification (CM)185.xx )and any of the below on same day or after the prostate cancer claim: * At least one inpatient claim with a primary or secondary diagnosis indicating bone metastases (ICD 9 CM 198.5 or Healthcare Common Procedure Coding System (HCPCS) code for a treatment indicative of bone metastases OR * At least two outpatient claims with a primary or secondary diagnosis indicating bone metastases (ICD 9 CM 198.5 or HCPCS code for a treatment indicative of bone metastases, with a minimum of 30 days between claims. Exclusion Criteria: * Subjects with a diagnosis of a cancer other than prostate cancer - defined as the presence of one inpatient or two outpatient claims with a primary or secondary diagnosis of malignant neoplasms (ICD-9-CM 140.xx-171.xx, 174.xx-184.xx,186.xx-195.xx,200.xx-209.3x, 230.xx-239.xx) - in the 12-month pre-index period. * Subjects with any claim for a primary or secondary diagnosis indicating bone metastases (ICD-9-CM 198.5) or any treatment indicative of bone metastases in the 12-month pre-index period. * Patients who had a SRE in the 12-month pre-index period. * Subjects without continuous enrollment for at least 12 months before the index date. * Subjects without continuous eligibility for at least 6 months after the index date. * Subjects that are female. * Subjects that have negative costs. * Subjects that are less than 45 years of age on the index date.

Locations (1)

Unnamed facility

Whippany, New Jersey, United States

Outcomes

Primary Outcomes

Distribution of treatment types among lines of therapy

Possible Treatment Types: Sipuleucel-T, Abiraterone, Enzalutamide, Docetaxel, Cabazitaxel, Radium-223, Anti-Androgens, All other chemotherapy(oral and injectables), Radiation therapy

Time frame: Up to 6 months

Time to treatment (days)

Time frame: Up to 6 months

Duration of treatment (days)

Time frame: Up to 6 months

Number of patients on each drug or drug combination

Drug: Sipuleucel-T, Abiraterone, Enzalutamide, Docetaxel, Cabazitaxel, Radium-223, Anti-Androgens, All other chemotherapy(oral and injectables), Radiation therapy

Time frame: Up to 6 months

Number of inpatient visits per patient